Iovance Biotherapeutics Inc (IOVA)

$5.00 +0.34 (7.30%)
Market Cap 2.23B
Revenue (ttm) 263.50M
Net Income (ttm) -390.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.38%
Debt to Equity Ratio 0.00
Volume 23,478,500
Avg Vol 15,468,318
Day's Range N/A - N/A
Shares Out 446.50M
Stochastic %K 91%
Beta 0.70
Analysts Strong Sell
Price Target $7.32

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
AirForce7
AirForce7 Jul. 19 at 3:39 PM
$IOVA you better prepare for a short squeeze next week 10$ + min i thik....
0 · Reply
GasparGaspacio
GasparGaspacio Jul. 19 at 3:33 PM
$IOVA IOVA stock price gonna get fried like Friedman!!!!!
1 · Reply
AlbanianMerc
AlbanianMerc Jul. 19 at 3:33 PM
$IOVA The power of CNPV Hernexeos was approved for adults with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations as detected by an FDA-authorized test. The application was filed on January 13, 2026 and was approved 44 days later.
0 · Reply
djcal
djcal Jul. 19 at 3:27 PM
$IOVA @Bilosellhigher Your numbers are somewhat inline with what I posted on Friday.
0 · Reply
djcal
djcal Jul. 19 at 3:24 PM
$IOVA
0 · Reply
AirForce7
AirForce7 Jul. 19 at 3:23 PM
$IOVA it will be quick to reach the price reached after approval @ AROUND 14 - 18$
0 · Reply
Bilosellhigher
Bilosellhigher Jul. 19 at 3:20 PM
$IOVA i asked ChatGPT what the projected stock price for IOVA would be in late 2026 following NSCLC data release assuming : 450M shares outstanding, VM=50%, and 2026 revenue of $370M For ORR>20%: mDOR>12 months $7.77-11 mDOR>16 months $11-15.56 mDOR>20 months $17.8-24.4 mDOR>24 months $22.2-31.1 If ORR increased to>25% the numbers are: mDOR>12 months $11-14.4 mDOR>16 months $14.4-20 mDOR>20 months $22.2-33.3 mDOR>24 months $29-40 Assuming the FDA approves Amtagvi for 2L NSCLC in late 2027, shares outstanding increased to 500M, and no major competive setbacks the projections for late 2027 with ORR>20% are: mDOR>12 months $14-20 mDOR>16 months $20-28 mDOR>20 months $28-40 mDOR>24 months $36-52 For ORR>25% the numbers are: mDOR>12 months $18-26 mDOR>16 months $26-36 mDOR>20 months $36-52 mDOR>24 months $48-70
3 · Reply
tedevan
tedevan Jul. 19 at 3:00 PM
$IOVA
0 · Reply
JohnEss
JohnEss Jul. 19 at 2:43 PM
$IOVA I think market is missing the macro picture. It's pricing IOVA mostly on melanoma ($1B+), completely ignoring the Non-Small Cell Lung Cancer (NSCLC) pipeline. • The 2027 NSCLC catalyst represents a massive $10 Billion opportunity if not more . Management is targeting FDA accelerated approval & launch in H2 2027. Much faster Wall Street thinks. • Phase 2 lung cancer data showed a 25.6% ORR (double standard of care) and a 72% disease control rate. Median duration of response not even reached at 25-month follow-up. Highly durable. • TIL therapy uses the body’s natural tumor-fighting cells. No messy genetic engineering required; it targets the exact mutations of solid tumors. Versus CAR-T • Transitioning to the centralized ICTC facility expanded gross margins to 50% and fixed past third-party manufacturing bottlenecks. • 26% short interest on the free float. Institutional ownership skyrocketed over the last 6 months to 73-77%. Tight float + impending data drops = massive coil.
2 · Reply
Fire_Truck
Fire_Truck Jul. 19 at 2:14 PM
$IOVA Friday volume 🤔 157%
0 · Reply
Latest News on IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jul 17, 2026, 5:15 PM EDT - 1 day ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Slides: Corporate presentation

Jun 30, 2026, 7:00 AM EDT - 19 days ago

Iovance Biotherapeutics Slides: Corporate presentation

Iovance Biotherapeutics files automatic mixed securities shelf

2026-06-18T20:35:12.000Z - 4 weeks ago

Iovance Biotherapeutics files automatic mixed securities shelf

Iovance Biotherapeutics Transcript: AGM 2026

Jun 10, 2026, 11:00 AM EDT - 5 weeks ago

Iovance Biotherapeutics Transcript: AGM 2026

Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 1:25 PM EDT - 6 weeks ago

Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

Iovance receives Australian approval of Amtagvi for advanced melanoma

2026-06-03T20:45:39.000Z - 6 weeks ago

Iovance receives Australian approval of Amtagvi for advanced melanoma

Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

Jun 3, 2026, 4:05 PM EDT - 6 weeks ago

Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

2026-06-01T13:15:52.000Z - 6 weeks ago

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Jun 1, 2026, 7:30 AM EDT - 6 weeks ago

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Iovance Biotherapeutics to Present at Upcoming Conference

May 21, 2026, 8:05 AM EDT - 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

2026-05-08T00:11:03.000Z - 2 months ago

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

2026-05-07T13:16:25.000Z - 2 months ago

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

2026-05-07T13:15:56.000Z - 2 months ago

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

2026-05-07T13:14:41.000Z - 2 months ago

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

Iovance Biotherapeutics Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Iovance Biotherapeutics Earnings release: Q1 2026

Iovance Biotherapeutics Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Iovance Biotherapeutics Quarterly report: Q1 2026

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

May 7, 2026, 7:05 AM EDT - 2 months ago

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing

Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Apr 27, 2026, 8:01 AM EDT - 2 months ago

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing

Replimune CRL positive for Iovance in near-term, says Chardan

2026-04-10T17:43:13.000Z - 3 months ago

Replimune CRL positive for Iovance in near-term, says Chardan

REPL

Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 9:30 AM EDT - 4 months ago

Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

2026-03-05T12:39:20.000Z - 4 months ago

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:50 AM EST - 4 months ago

Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Iovance Biotherapeutics to Present at Upcoming Conferences

Feb 26, 2026, 8:00 AM EST - 5 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

2026-02-25T14:14:16.000Z - 5 months ago

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

Iovance Biotherapeutics price target raised to $11 from $10 at Barclays

2026-02-25T10:26:51.000Z - 5 months ago

Iovance Biotherapeutics price target raised to $11 from $10 at Barclays

Iovance upgraded to Outperform from Market Perform at Citizens

2026-02-25T09:45:12.000Z - 5 months ago

Iovance upgraded to Outperform from Market Perform at Citizens

Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

2026-02-24T22:30:40.000Z - 5 months ago

Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Iovance Biotherapeutics Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Iovance Biotherapeutics Annual report: Q4 2025

Iovance Biotherapeutics Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Iovance Biotherapeutics Earnings release: Q4 2025

Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)

2026-02-24T12:19:34.000Z - 5 months ago

Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Feb 24, 2026, 7:00 AM EST - 5 months ago

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Feb 24, 2026, 7:00 AM EST - 5 months ago

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Iovance Biotherapeutics Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 5 months ago

Iovance Biotherapeutics Slides: Corporate presentation

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Feb 11, 2026, 4:05 PM EST - 5 months ago

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Feb 5, 2026, 5:15 PM EST - 5 months ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Iovance Biotherapeutics Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 6 months ago

Iovance Biotherapeutics Slides: Corporate presentation

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Iovance Biotherapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Iovance Biotherapeutics Quarterly report: Q3 2025

Iovance Biotherapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Iovance Biotherapeutics Earnings release: Q3 2025

Iovance Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:00 AM EDT - 11 months ago

Iovance Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Iovance Biotherapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 8:00 AM EDT - 11 months ago

Iovance Biotherapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 18, 2025, 4:15 PM EDT - 11 months ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Iovance Biotherapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Quarterly report: Q2 2025

Iovance Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings release: Q2 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 23, 2025, 12:08 PM EDT - 1 year ago

Here's why Iova stock surged 32% today and why the rally might not be over

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 15, 2025, 7:30 AM EDT - 1 year ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 9:04 AM EDT - 1 year ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 14, 2025, 7:30 AM EDT - 1 year ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 10, 2025, 8:18 AM EDT - 1 year ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 28, 2025, 7:46 AM EDT - 1 year ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 20, 2025, 9:07 AM EDT - 1 year ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 18, 2025, 8:38 AM EDT - 1 year ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 1 year ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

AirForce7
AirForce7 Jul. 19 at 3:39 PM
$IOVA you better prepare for a short squeeze next week 10$ + min i thik....
0 · Reply
GasparGaspacio
GasparGaspacio Jul. 19 at 3:33 PM
$IOVA IOVA stock price gonna get fried like Friedman!!!!!
1 · Reply
AlbanianMerc
AlbanianMerc Jul. 19 at 3:33 PM
$IOVA The power of CNPV Hernexeos was approved for adults with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations as detected by an FDA-authorized test. The application was filed on January 13, 2026 and was approved 44 days later.
0 · Reply
djcal
djcal Jul. 19 at 3:27 PM
$IOVA @Bilosellhigher Your numbers are somewhat inline with what I posted on Friday.
0 · Reply
djcal
djcal Jul. 19 at 3:24 PM
$IOVA
0 · Reply
AirForce7
AirForce7 Jul. 19 at 3:23 PM
$IOVA it will be quick to reach the price reached after approval @ AROUND 14 - 18$
0 · Reply
Bilosellhigher
Bilosellhigher Jul. 19 at 3:20 PM
$IOVA i asked ChatGPT what the projected stock price for IOVA would be in late 2026 following NSCLC data release assuming : 450M shares outstanding, VM=50%, and 2026 revenue of $370M For ORR>20%: mDOR>12 months $7.77-11 mDOR>16 months $11-15.56 mDOR>20 months $17.8-24.4 mDOR>24 months $22.2-31.1 If ORR increased to>25% the numbers are: mDOR>12 months $11-14.4 mDOR>16 months $14.4-20 mDOR>20 months $22.2-33.3 mDOR>24 months $29-40 Assuming the FDA approves Amtagvi for 2L NSCLC in late 2027, shares outstanding increased to 500M, and no major competive setbacks the projections for late 2027 with ORR>20% are: mDOR>12 months $14-20 mDOR>16 months $20-28 mDOR>20 months $28-40 mDOR>24 months $36-52 For ORR>25% the numbers are: mDOR>12 months $18-26 mDOR>16 months $26-36 mDOR>20 months $36-52 mDOR>24 months $48-70
3 · Reply
tedevan
tedevan Jul. 19 at 3:00 PM
$IOVA
0 · Reply
JohnEss
JohnEss Jul. 19 at 2:43 PM
$IOVA I think market is missing the macro picture. It's pricing IOVA mostly on melanoma ($1B+), completely ignoring the Non-Small Cell Lung Cancer (NSCLC) pipeline. • The 2027 NSCLC catalyst represents a massive $10 Billion opportunity if not more . Management is targeting FDA accelerated approval & launch in H2 2027. Much faster Wall Street thinks. • Phase 2 lung cancer data showed a 25.6% ORR (double standard of care) and a 72% disease control rate. Median duration of response not even reached at 25-month follow-up. Highly durable. • TIL therapy uses the body’s natural tumor-fighting cells. No messy genetic engineering required; it targets the exact mutations of solid tumors. Versus CAR-T • Transitioning to the centralized ICTC facility expanded gross margins to 50% and fixed past third-party manufacturing bottlenecks. • 26% short interest on the free float. Institutional ownership skyrocketed over the last 6 months to 73-77%. Tight float + impending data drops = massive coil.
2 · Reply
Fire_Truck
Fire_Truck Jul. 19 at 2:14 PM
$IOVA Friday volume 🤔 157%
0 · Reply
GasparGaspacio
GasparGaspacio Jul. 19 at 1:52 PM
$IOVA uh oh
1 · Reply
BioCrazy1
BioCrazy1 Jul. 19 at 1:48 PM
$IOVA Thanks to the morons reposting brain dead comments you have effectively had yourself blocked! Congrats! See ya!
0 · Reply
Always_neutral
Always_neutral Jul. 19 at 1:41 PM
$IOVA Here is a challenge: If it doesn't go down to 1 next week, you leave this board!
1 · Reply
TheWinningStock
TheWinningStock Jul. 19 at 1:29 PM
$IOVA ......🤑🚀 https://seekingalpha.com/news/4600778-iovance-wins-australian-nod-melanoma-drug
0 · Reply
GasparGaspacio
GasparGaspacio Jul. 19 at 10:09 AM
$IOVA
2 · Reply
Kaerasori
Kaerasori Jul. 19 at 9:46 AM
$IOVA Will be high teens end of the year. Its on cruise control.
4 · Reply
tedevan
tedevan Jul. 19 at 5:16 AM
$IOVA earnings $6-$6.50 then pull back to mid to high $5's then blast to high 7's mid $8's on interim lung data readout.
3 · Reply
mikesterz7
mikesterz7 Jul. 19 at 5:06 AM
$IOVA The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings.
1 · Reply
tedevan
tedevan Jul. 19 at 5:04 AM
$IOVA
0 · Reply
Lilwopjob
Lilwopjob Jul. 19 at 4:13 AM
$IOVA checked Stocktwits, went and saw the Odyssey, came home, checking Stocktwits…it’s Saturday. I may have a problem
3 · Reply
pcstock12
pcstock12 Jul. 19 at 1:58 AM
$ARWR Waiting for all time high. Which other bio stocks are worth to check out? Bought small amt of $IOVA $HUMA $OTLK
5 · Reply
locallab
locallab Jul. 19 at 1:54 AM
$IOVA F the FUD attempts. This company is the future of cancer treatment. Bears are idiots. Been steadily going up to where it should have already been. Only reason it dropped so much was a bad cfo with poor outlook and if you didn't take advantage of the gift of 1.75 for months then go ahead and start buying, because this is going to be a historical company in oncology and biotech. If you can't understand the preliminary data means the bears are F'd then you need to go invest in the AI bubble and stay out of biotech.
1 · Reply